Dr. Asch is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1122 NE 13th St
Oklahoma City, OK 73117Phone+1 405-271-8299Fax+1 405-271-9180
Education & Training
- New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 1982 - 1984
- Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 1979 - 1982
- Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1979
- Swarthmore CollegeAB
Certifications & Licensure
- OK State Medical License 2014 - 2025
- NC State Medical License 2006 - 2015
- NY State Medical License 1982 - 2008
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Research Award JDRF, 2001
- Research Career Development Award NIH, 1990
- Stratton Foundation Award 1989
- Join now to see all
Clinical Trials
- Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting Start of enrollment: 2010 Dec 02
- Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Start of enrollment: 2012 Aug 08
- Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors Start of enrollment: 2015 Aug 05
- Join now to see all
Publications & Presentations
PubMed
- Impact of Primary Disease Site of Involvement by Early-Stage Follicular Lymphoma on Patient Outcomes.Olivia Davis, Carmen Lessani, Rana Kasht, Andrew Cohoon, Sami Ibrahimi
Clinical Lymphoma, Myeloma & Leukemia. 2024-12-01 - Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma.Joseph E Maakaron, Adam Asch, Leslie Popplewell, Graham P Collins, Ian W Flinn
Blood Advances. 2024-11-26 - 1 citationsStat3 Inhibitors TTI-101 and SH5-07 Suppress Bladder Cancer Cell Survival in 3D Tumor Models.Surya P Singh, Gopal Pathuri, Adam S Asch, Chinthalapally V Rao, Venkateshwar Madka
Cells. 2024-08-31
Journal Articles
- A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphomaPark SI, Grover NS, Olajide O, Asch AS, Wall JG, Richards KL, Sobol AL, Deal AM, Ivanova A, Foster MC, Muss HB, Shea TC, Br J Haematol, 1/22/2016
- Emerging links among Chromosome Instability (CIN), cancer, and agingRao CV, Asch AS, Yamada HY, Mol Carcinog, 1/17/2016
- Caenorhabditis elegans: a model system for anti-cancer drug discovery and therapeutic target identificationKobet RA, PanX, Zhang B, Pak SC, Asch AS, LeeMH, Biomol. Ther., 1/1/2014
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Na¥ve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive...Adam S. Asch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b ResultsAdam S. Asch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Activation of the Proton-Sensing GPR4 Receptor Stimulates Vascular Endothelial Cell Inflammatory Responses Revealed by Transcriptome AnalysisDong L, Li, Leffler N, Asch AS, Yang Y, 102nd Annual Meeting of the American Association for Cancer Research, 1/2/2011
- Join now to see all
Lectures
- Role of Somatic Mutations and Clonal Thrombopoiesis in Immune Thrombocytopenia2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Thrombocytopenia Is a Biomarker for Response in Patients Treated with Anti PD-1/Pdl-1 Therapy2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Role of translational control in lineage commitment and plasticity1/1/2005
- Join now to see all
Press Mentions
- Honorees Named for Health Care Heroes EventDecember 10th, 2019
- Pulling Back the Curtain: Roy Silverstein, MDDecember 1st, 2019
- Oklahoma Man Finds Hope from Revolutionary New Cancer TreatmentNovember 28th, 2019
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: